LPS differentially affects expression of CD14 and CCR2 in monocyte subsets of Post-STEMI patients with hyperglycemia. (September 2022)
- Record Type:
- Journal Article
- Title:
- LPS differentially affects expression of CD14 and CCR2 in monocyte subsets of Post-STEMI patients with hyperglycemia. (September 2022)
- Main Title:
- LPS differentially affects expression of CD14 and CCR2 in monocyte subsets of Post-STEMI patients with hyperglycemia
- Authors:
- Blanks, Anson M.
Pedersen, Lauren N.
Caslin, Heather L.
Mihalick, Virginia L.
Via, Jeremy
Canada, Justin M.
Van Tassell, Benjamin
Carbone, Salvatore
Abbate, Antonio
Lee Franco, R. - Abstract:
- Highlights: Post-infarction intermediate monocyte CD14 is lower in impaired random glucose compared to normal post-STEMI patients. Lipopolysaccharide decreases classical and intermediate monocyte CCR2 and CD14, post-infarction. Impaired random glucose reduces lipopolysaccharide induced classical subset CCR2. Non-classical CCR2 correlates with serum glucose following lipopolysaccharide activation. Abstract: Aims: Following ST-segment elevation myocardial infarction (STEMI), recruitment and activation of monocytes [classical (CD14 ++ CD16 - CCR2 ++ ), intermediate (CD14 ++ CD16 + CCR2 + ), non-classical (CD14 Low CD16 ++ CCR2 Low )] are needed for myocardial wound healing. Monocyte surface receptor CC chemokine receptor type 2 (CCR2) is responsible for monocyte chemotaxis to sites of inflammation and the lipopolysaccharide (LPS)-binding protein co-receptor, CD14, is involved in pro-inflammatory monocyte activation. The purpose of this investigation was to determine the effects of ex-vivo LPS activation on monocyte subset CD14 and CCR2 expression in post-STEMI individuals with normal and elevated random blood glucose. Methods: Post-STEMI subjects were identified as normal random glucose (NG, <98 mg/dL, n = 13) or impaired random glucose (IG, ≥98 mg/dL, n = 26) and monocytes were analyzed for non-activated and LPS-activated (1 µg/mL for 4 h) CCR2 and CD14 expression. Results: Non-activated intermediate monocytes from IG showed decreased CD14 expression when compared to NG, whichHighlights: Post-infarction intermediate monocyte CD14 is lower in impaired random glucose compared to normal post-STEMI patients. Lipopolysaccharide decreases classical and intermediate monocyte CCR2 and CD14, post-infarction. Impaired random glucose reduces lipopolysaccharide induced classical subset CCR2. Non-classical CCR2 correlates with serum glucose following lipopolysaccharide activation. Abstract: Aims: Following ST-segment elevation myocardial infarction (STEMI), recruitment and activation of monocytes [classical (CD14 ++ CD16 - CCR2 ++ ), intermediate (CD14 ++ CD16 + CCR2 + ), non-classical (CD14 Low CD16 ++ CCR2 Low )] are needed for myocardial wound healing. Monocyte surface receptor CC chemokine receptor type 2 (CCR2) is responsible for monocyte chemotaxis to sites of inflammation and the lipopolysaccharide (LPS)-binding protein co-receptor, CD14, is involved in pro-inflammatory monocyte activation. The purpose of this investigation was to determine the effects of ex-vivo LPS activation on monocyte subset CD14 and CCR2 expression in post-STEMI individuals with normal and elevated random blood glucose. Methods: Post-STEMI subjects were identified as normal random glucose (NG, <98 mg/dL, n = 13) or impaired random glucose (IG, ≥98 mg/dL, n = 26) and monocytes were analyzed for non-activated and LPS-activated (1 µg/mL for 4 h) CCR2 and CD14 expression. Results: Non-activated intermediate monocytes from IG showed decreased CD14 expression when compared to NG, which was maintained following LPS-activation. The NG group showed a larger absolute reduction in classical CCR2 expression, leading to a significant difference between NG and IG following LPS-activation. Conclusion: Results suggest a heightened response to pro-inflammatory activation in IG following STEMI, which may impair or delay post-STEMI myocardial healing, and thus increase the incidence of chronic heart failure. NIH 1R34HL121402. … (more)
- Is Part Of:
- Diabetes research and clinical practice. Volume 191(2022)
- Journal:
- Diabetes research and clinical practice
- Issue:
- Volume 191(2022)
- Issue Display:
- Volume 191, Issue 2022 (2022)
- Year:
- 2022
- Volume:
- 191
- Issue:
- 2022
- Issue Sort Value:
- 2022-0191-2022-0000
- Page Start:
- Page End:
- Publication Date:
- 2022-09
- Subjects:
- Monocyte -- STEMI -- CCR2 -- CD14 -- CHF -- LPS -- Glucose -- Inflammation
Diabetes -- Periodicals
Diabetes Mellitus -- Periodicals
616.462 - Journal URLs:
- http://www.sciencedirect.com/science/journal/01688227 ↗
http://www.clinicalkey.com.au/dura/browse/journalIssue/01688227 ↗
http://www.clinicalkey.com/dura/browse/journalIssue/01688227 ↗
http://www.sciencedirect.com/science/journal/01688227 ↗
http://www.elsevier.com/journals ↗ - DOI:
- 10.1016/j.diabres.2022.110077 ↗
- Languages:
- English
- ISSNs:
- 0168-8227
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3579.603700
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 23979.xml